Cargando…

77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico

ABSTRACT IMPACT: The implementation of nasal nitric oxide (nNO) as a diagnostic tool to understand the phenotypic/genotypic profiles of Primary Ciliary Dyskinesia (PCD) in Puerto Rico (PR) will be translated in early disease diagnosis, avoidance of comorbidities, and increase survival in our populat...

Descripción completa

Detalles Bibliográficos
Autores principales: De Jesus Rojas, Wilfredo, Morou-Bermudez, Evangelia, Wojna, Valerie, Carlo, Simon, Mosquera, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827983/
http://dx.doi.org/10.1017/cts.2021.667
_version_ 1784647762397102080
author De Jesus Rojas, Wilfredo
Morou-Bermudez, Evangelia
Wojna, Valerie
Carlo, Simon
Mosquera, Ricardo
author_facet De Jesus Rojas, Wilfredo
Morou-Bermudez, Evangelia
Wojna, Valerie
Carlo, Simon
Mosquera, Ricardo
author_sort De Jesus Rojas, Wilfredo
collection PubMed
description ABSTRACT IMPACT: The implementation of nasal nitric oxide (nNO) as a diagnostic tool to understand the phenotypic/genotypic profiles of Primary Ciliary Dyskinesia (PCD) in Puerto Rico (PR) will be translated in early disease diagnosis, avoidance of comorbidities, and increase survival in our population. OBJECTIVES/GOALS: This study aims to evaluate the role of nNO levels in PCD diagnosis in the Puerto Rican population. Also, we aim to describe the clinical, genetic, and physiological characteristics of PCD in Puerto Ricans to develop a better understanding of the disease. METHODS/STUDY POPULATION: We plan to conduct a cross-sectional study on participants recruited from patients of the Pediatric Rare Lung and Asthma Institute in PR. We will compare nNO levels among genetically confirmed PCD patients, suspected PCD patients with variant of unknown significance (VUS) mutations, suspected PCD patients without genetic mutations, and age-matched healthy subjects. We plan to analyze clinical data and genetic variants to understand the natural history of the disease. The nNO measurements will be completed following previous published protocols. We will also assess the accuracy of the nNO measurements by repeating the measurements two weeks after the initial measurement. RESULTS/ANTICIPATED RESULTS: We hypothesize that many of the VUS present in our population may represent potential new founder mutations not previously reported in the literature. Our expectation is to identify new atypical PCD phenotypes contemplating the heterogenous genetic Puerto Rican pool. We anticipate that nNO levels will help to screen, identify, and confirm diagnosis of patients with clinical PCD in PR. Our findings will be translated in avoidance of further comorbidities and mortality due to earlier disease PCD diagnosis and will expand our genetic understanding about PCD in PR and other diverse populations with heterogenous genetic admixture. DISCUSSION/SIGNIFICANCE OF FINDINGS: We present a significant and novel research proposal that plan to impact the quality of life of patients living with PCD in PR. The implementation of state-of-the-art diagnostic tools like nNO measurement will positively impact and expand our current capabilities to diagnose rare lung diseases like PCD on the island.
format Online
Article
Text
id pubmed-8827983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88279832022-02-28 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico De Jesus Rojas, Wilfredo Morou-Bermudez, Evangelia Wojna, Valerie Carlo, Simon Mosquera, Ricardo J Clin Transl Sci Precision Medicine ABSTRACT IMPACT: The implementation of nasal nitric oxide (nNO) as a diagnostic tool to understand the phenotypic/genotypic profiles of Primary Ciliary Dyskinesia (PCD) in Puerto Rico (PR) will be translated in early disease diagnosis, avoidance of comorbidities, and increase survival in our population. OBJECTIVES/GOALS: This study aims to evaluate the role of nNO levels in PCD diagnosis in the Puerto Rican population. Also, we aim to describe the clinical, genetic, and physiological characteristics of PCD in Puerto Ricans to develop a better understanding of the disease. METHODS/STUDY POPULATION: We plan to conduct a cross-sectional study on participants recruited from patients of the Pediatric Rare Lung and Asthma Institute in PR. We will compare nNO levels among genetically confirmed PCD patients, suspected PCD patients with variant of unknown significance (VUS) mutations, suspected PCD patients without genetic mutations, and age-matched healthy subjects. We plan to analyze clinical data and genetic variants to understand the natural history of the disease. The nNO measurements will be completed following previous published protocols. We will also assess the accuracy of the nNO measurements by repeating the measurements two weeks after the initial measurement. RESULTS/ANTICIPATED RESULTS: We hypothesize that many of the VUS present in our population may represent potential new founder mutations not previously reported in the literature. Our expectation is to identify new atypical PCD phenotypes contemplating the heterogenous genetic Puerto Rican pool. We anticipate that nNO levels will help to screen, identify, and confirm diagnosis of patients with clinical PCD in PR. Our findings will be translated in avoidance of further comorbidities and mortality due to earlier disease PCD diagnosis and will expand our genetic understanding about PCD in PR and other diverse populations with heterogenous genetic admixture. DISCUSSION/SIGNIFICANCE OF FINDINGS: We present a significant and novel research proposal that plan to impact the quality of life of patients living with PCD in PR. The implementation of state-of-the-art diagnostic tools like nNO measurement will positively impact and expand our current capabilities to diagnose rare lung diseases like PCD on the island. Cambridge University Press 2021-03-30 /pmc/articles/PMC8827983/ http://dx.doi.org/10.1017/cts.2021.667 Text en © The Association for Clinical and Translational Science 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Precision Medicine
De Jesus Rojas, Wilfredo
Morou-Bermudez, Evangelia
Wojna, Valerie
Carlo, Simon
Mosquera, Ricardo
77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title_full 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title_fullStr 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title_full_unstemmed 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title_short 77680 Nasal Nitric Oxide Levels as a Diagnostic Tool for Primary Ciliary Dyskinesia in Puerto Rico
title_sort 77680 nasal nitric oxide levels as a diagnostic tool for primary ciliary dyskinesia in puerto rico
topic Precision Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827983/
http://dx.doi.org/10.1017/cts.2021.667
work_keys_str_mv AT dejesusrojaswilfredo 77680nasalnitricoxidelevelsasadiagnostictoolforprimaryciliarydyskinesiainpuertorico
AT moroubermudezevangelia 77680nasalnitricoxidelevelsasadiagnostictoolforprimaryciliarydyskinesiainpuertorico
AT wojnavalerie 77680nasalnitricoxidelevelsasadiagnostictoolforprimaryciliarydyskinesiainpuertorico
AT carlosimon 77680nasalnitricoxidelevelsasadiagnostictoolforprimaryciliarydyskinesiainpuertorico
AT mosqueraricardo 77680nasalnitricoxidelevelsasadiagnostictoolforprimaryciliarydyskinesiainpuertorico